Sands Capital Life Sciences Pulse Fund II, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT)

Filing Manager: Sands Capital Life Sciences Pulse Fund II, L.P.
Reporting Manager: Sands Capital Life Sciences Pulse Fund II, L.P.
Security: Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol: IKT
Shares outstanding: 120,545,972 shares
Disclosed Ownership: 13,018,965 shares
Ownership: 11%
Form type: SCHEDULE 13G/A
Filing time: 13 Feb 2026, 11:30:46 UTC
Date of event: 31 Dec 2025
Previous filing: 13 Aug 2025
SEC: View on sec.gov

Reporting Managers (3)

Name	Ownership	Shares Owned	shared voting power	Signature	Title
Sands Capital Life Sciences Pulse Fund II, L.P.	11%	13,018,965	13,018,965	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Sands Capital Alternatives, LLC	11%	13,018,965	13,018,965	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel
SANDS FRANK M.	11%	13,018,965	13,018,965	/s/ Frank M. Sands	Frank M. Sands